Le Lézard
Classified in: Health, Covid-19 virus
Subjects: PDT, TRI, IMA

European based rapid PCR-COVID19 home-test company Selfdiagnostics is to submit request for authorisation


TALLINN, Estonia, Dec. 2, 2020 /PRNewswire/ -- European based company Selfdiagnostics (GER, EST) plans to submit request for authorisation of its molecular diagnostic test for home and for point of care use ? to detect the coronavirus SARS-CoV-2. Selfdiagnostics rapid PCR is first multifunctional test which allows to detect simultaneously COVID and influenza from one non-invasive nasal swab. 

"Selfdiagnostics' instrument free Multitest is based on nucleic acid amplification and has significantly lower false negative results than the serologic test. The test is fully comparable in its sensitivity and specificity to molecular diagnostics home test approved November 20 by FDA as shown by testing of clinical reference samples from COVID 19 patients," said member of scientific advisory board of Selfdiagnostics PhD, Prof Tamas Bartfai.

CEO and co-founder of Selfdiagnostics Marko Lehes said that home use PCR is revolutionary approach to bring laboratory grade accuracy to endusers hands. "Selfdiagnostics has proved its technology with sexually transmitted diseases and now after successful interim clinical study introduces COVID and influenza multitest in current virus season and scales up production in Europe," said Lehes.

The Selfdiagnotics rapid PCR multitest is based on isothermal PCR which is already approved by FDA for home use and paves the way for tremendous increase of testing cases which is still a key step to stop the pandemics.

Selfdiagnostics COVID multitest is confirmative because of running PCR, which cannot be said for antigen tests. The test is faster than laboratory PCR ? time from sampling to result in only 40 minutes and the test is non-invasive ? runs with easy taken nasal swab or/and saliva. People who have symptoms or have been in contact with a positive patient, can be tested anywhere and anytime outside of lab ? at home, at workplaces, doctors offices, pharmacies etc.

About Selfdiagnostics

Selfdiagnostics Deutschland GmbH brings laboratory-grade precision home medical testing to ordinary users and offers the world's smallest application of PCR (polymerase chain reaction) technology (http://selfdiagnostics.eu/sdx-multitest/). This unique product paves the way for bigger changes in medicine in regard to patients taking the first steps toward diagnosing illnesses. Doing so Selfdiagnostics has developed a unique molecular diagnostics platform for medical point of care devices. Selfdiagnostics proprietary technology allows different DNA and RNA detection purposes like for respiratory (Covid, Influenza, TB), blood born (HIV, Hepatitis) and urine (CT, NG, MG, TV, Zika) based diseases.

Photo - https://mma.prnewswire.com/media/1344617/Selfdiagnostics_Marko_Lehes_CEO.jpg  


These press releases may also interest you

at 08:40
The "United States Self-Monitoring Blood Glucose Devices Market Growth, Share, Size, Trends, Analysis and Forecast (2024 - 2032)" report has been added to ResearchAndMarkets.com's offering. The U.S. Self-Monitoring Blood Glucose Devices market size...

at 08:35
Arch Insurance North America (Arch), a provider of specialized insurance and risk management solutions, today unveiled its latest products available through the Arch APEX? digital platform. Participant Accident coverage is now available for child...

at 08:35
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B...

at 08:35
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial...

at 08:30
Solitario Resources Corp. ("Solitario") is pleased to report that it has discovered another high-grade gold zone on its Golden Crest project, named Sleeping Beauty. Recently received assay results from reconnaissance rock sampling of...

at 08:30
Camber Energy, Inc. ("Camber" or the "Company"), today announced that on March 26, 2024, the U.S. Patent and Trademark Office (USPTO) issued U.S. patent11,942,776 entitled "Electric Transmission Line Ground Fault Prevention...



News published on and distributed by: